Could a few shots replace weeks of IV antibiotics for joint infections?
NCT ID NCT05046860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests dalbavancin, a long-acting antibiotic given as a few shots over two months, for infections that occur after hip or knee replacement surgery. The standard treatment requires 12 weeks of daily antibiotics, which can be hard to tolerate and complete. The trial includes adults with a first infection of the joint replacement caused by staphylococcus bacteria, treated surgically. Researchers want to see if this simpler approach is effective and well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dalbavancin
- What this could lead to
- If successful, this could offer a simpler, shorter antibiotic regimen for joint replacement infections, reducing the need for daily IVs and improving patient compliance.
- What could go wrong
- This is a small, early-phase study with only 43 participants. The long-term effectiveness and safety compared to standard 12-week antibiotics are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 43 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2022
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age greater than or equal to 18 years * First monomicrobial osteoarticular infection of knee or hip prosthesis with staphylococcus sensitive to dalbavancin (determined by a minimum inhibitory concentration by microdilution of the strain in question for vancomycin less than or equal to 2mg/L) and rifampicin, treated surgically by debridement, antibiotics and implant retention with change of moving parts (acute infections) or change in 1 stage (chronic infections) * Social security affiliation * Signature of informed consent Exclusion Criteria: * Hypersensitivity to glycopeptides or rifampin or to any of the excipients * Porphyrias * Probabilistic antibiotic treatment not administered within 24 hours of surgery * Probabilistic antibiotic treatment that did not take into account the bacterium causing the infection in its spectrum * Acute hematogenous infection (acute secondary) * Use of background treatment incompatible with the inducing effect of rifampicin (see Summary of Product Characteristics for rifampicin) * Contraindications to rifampin therapy: Moderate to severe impairment of liver function, patients with a history of hypersensitivity to other rifamycins, porphyria. Hepatic cirrhosis * Use of ototoxic therapy, such as an aminoglycoside * Renal function with glomerular filtration rate less than 30 ml/min as measured by MDRD (Modification of Diet in Renal Disease) * Pregnant and breastfeeding women: at inclusion a blood pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a physician of her choice. * Women of childbearing age not using an effective method of contraception (pill, intrauterine device, vaginal ring, contraceptive skin patch, hormonal subcutaneous implant, surgical sterilization) * Protected persons defined in the following articles of the public health code: L. 1121-6: persons deprived of liberty by a judicial or administrative decision, persons hospitalized without consent and persons admitted to a health or social establishment for purposes other than research; L. 1121-8: adults subject to a legal protection measure or unable to express their consent; L. 1122-1-2: persons in emergency situations who are unable to give prior consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Osteoarticular infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP - Hôpital Ambroise-Paré
Boulogne-Billancourt, 92100, France
-
CHRU de TOURS
Tours, 37000, France
-
CHU de Nice
Nice, France
-
Centre Hospitalier de Tourcoing
Tourcoing, 59208, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.